www.circulogix.com Open in urlscan Pro
18.235.215.12  Public Scan

Form analysis
0 forms found in the DOM

Text Content

TOWARDS PERSONALIZEDWhy Rare Cells?How It WorksCirculogix In ActionThe
TeamCirculogix In The NewsContact Us






 *  
   
    
   
    
   
    
   
    
   
   TOWARDS PERSONALIZED MEDICINE
   
   ONE RARE CELL AT A TIME.

 * WHY RARE ENRICHMENT?
   
    
   
   The spread of cancer - called "metastasis" - is responsible for the
   overwhelming majority of cancer-related death. Metastatic disease is a highly
   complex series of events that involves: 1) cancer cells leaving their primary
   site to enter the bloodstream, 2) surviving in circulation, and 3) exiting
   the bloodstream at distant sites to colonize new tumors. Circulating Tumor
   Cells (CTCs) represent the rare tumor sub-population that successfully
   completes these events, and thus play a critical role in tumor dissemination.
   In addition to CTCs, recent studies suggest that other rare circulating
   cells, including Cancer Associated Fibroblasts (CAFs), operate in
   collaboration with CTCs to help establish metastases at secondary sites.
   
    
   
   Circulogix Inc is a liquid biopsy company that aims to bring innovative
   solutions for rare cell enrichment and characterization to the market. Our
   proprietary sized-based enrichment technologies sensitively and reliably
   capture rare cells of interest in an "expression agnostic" fashion, such that
   the true heterogeneity of a patient's disease can be preserved, analyzed and
   exploited for improved patient management.
   
    
   
    
   
   Our goals at Circulogix are two-fold:
   
    * To provide research scientists with sophisticated tools in a user-friendly
      workflow to investigate and better understand the underlying mechanisms
      governing metastases and tumor cell dissemination. 
   
   - and -
   
    * To empower clinicians with the ability to predict whether a course of
      treatment is suitable before treatment begins, monitor the efficacy of an
      on-going treatment in real-time, and expose new mechanisms of drug
      resistance for novel therapeutics via CTC- and rare cell-based assays.
   
    


 * HOW IT WORKS
   
   THE SIMPLE WORKFLOW FOR RARE CELL ENRICHMENT BY CIRCULOGIX
   
   1
   
   
   BLOOD SAMPLE
   
   Body fluids of interest (i.e. blood, urine, ascites) are collected from
   patients.
   
   2
   
   
   RARE CELL ENRICHMENT
   
   Samples are placed into the Circulogix FaCTChecker, our automated system for
   sample dilution, preservation and processing. Rare cells of interest are
   enriched onto CyteCatch slides, specially engineered microscope slides
   containing our platform for rare cell enrichment.
   
   3
   
   RARE CELL CHARACTERIZATION
   
   CyteCatch slides are removed from the FaCTChecker, and rare cells of interest
   are available for a wide range of downstream applications for their
   morphologic, molecular and functional characterization, including:
   
    * Multimarker Immunofluorescence/IHC
    * FISH and RNA ISH
    * NextGen Sequencing for (genomic and transcriptomic analyses)
    * Primary Tissue Culture 
   
   and many other assays.

 * CIRCULOGIX IN ACTION
   
   CIRCULOGIX INC IS FOCUSED ON THE DEVELOPMENT OF INNOVATIVE TECHNOLOGIES TO
   ENABLE MORPHOLOGIC, MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF RARE CELLS
   FOR PATIENT BENEFIT IN VARIETY OF DISEASE SETTINGS.
   
   CIRCULATING TUMOR CELL (CTC) IDENTIFICATION
   
    
   
   USING A PAN-CYTOKERATIN (CK) ANTIBODY (GREEN), CD45 ANTIBODY (RED, NOT
   SHOWN), AND DAPI FOR NUCLEAR VISUALIZATION (BLUE), CTCS PRESENT ON THE
   CYTECATCH SLIDES ARE IDENTIFIED AS NUCLEATED, CK POSITIVE, CD45 NEGATIVE
   CELLS WITH SIZE AND MORPHOLOGIC CRITERIA CONSISTENT WITH MALIGNANCY.
   
    
   
   Pictured: CTCs captured onto CyteCatch slides from a metastatic ovarian
   cancer patient.
   
   MOLECULAR CHARACTERIZATION OF CTCS BY IN-SITU HYBRIDIZATION (FISH OR RNA ISH)
   
    
   
   DNA ABERRATIONS, INCLUDING GENE COPY NUMBER, CHROMOSOMAL REARRANGEMENT AND
   GENE FUSION, ARE A HALLMARK TUMOR INITIATION AND PROGRESSION FOR MULTIPLE
   DISEASE TYPES. THE DETECTION OF THESE ABERRATIONS BY FISH ON CTCS COULD HELP
   PREDICT THE EFFICACY OF NUMEROUS THERAPIES DESIGNED TO SPECIFICALLY TARGET
   SUCH ANOMALIES.    
   
    
   
   Pictured: "Breakapart" FISH assay detecting a split signal of the ALK gene in
   a CTC enriched onto a CyteCatch slide from a metastatic, non-small cell lung
   cancer patient positive for ALK rearrangement.
   
   CHARACTERIZATION OF CTC CLUSTERS
   
    
   
   ALTHOUGH SEMINAL STUDIES DEMONSTRATE THE PROGNOSTIC AND PREDICTIVE VALUE OF
   CTCS AS SINGULAR EVENTS, A GROWING BODY OF EVIDENCE SUGGESTS THAT CTC
   CLUSTERS PROTECT CELLS FROM ANOIKIS, CONFER GREATER RESISTANCE TO CYTOTOXIC
   THERAPIES, AND INCREASE THE LIKELIHOOD FOR SUCCESSFULLY COLONIZING TUMORS AT
   SECONDARY SITES.
   
    
   
   Pictured: A cluster of nucleated, CK positive, CD45 negative CTCs enriched
   onto a CyteCatch slide from a metastatic breast cancer patient.
   
   VIABLE CTC ENRICHMENT FOR FUNCTIONAL CHARACTERIZATION
   
    
   
   THE STANDARD WORKFLOW PROTOCOL FOR RARE CELL ENRICHMENT CALLS FOR A BRIEF
   FIXATION STEP, WHICH LIMITS THE ABILITY TO PERFORM ANALYSES REQUIRING CELL
   VIABILITY. BY PRECISE MODIFICATION OF THE CYTECATCH SLIDE PORE ARCHITECTURE,
   OUR PROPRIETARY TECHNOLOGY AT CIRCULOGIX PERMITS THE ENRICHMENT OF VIABLE
   CTCS FOR DOWNSTREAM FUNCTIONAL APPLICATIONS.
   
    
   
   Pictured: Scanning electron micrograph of a live tumor cell captured on a
   viable CyteCatch slide.
   
   IDENTIFICATION OF CIRCULATING CANCER ASSOCIATED FIBROBLASTS (CCAFS)
   
    
   
   RECENT EVIDENCE INDICATES THAT CAFS DETECTED IN THE BLOOD OF CANCER PATIENTS
   ARE ASSOCIATED WITH THE PRESENCE OF METASTASES, IDENTIFYING THEM AS
   POTENTIALLY RELEVANT CLINICAL BIOMARKER FOR POOR PROGNOSIS.
   
    
   
   Pictured: Multimarker IF labeling a cluster of nucleated (DAPI; Blue) CTCs
   (Pan CK; Green), cCAFs (Fibroblast Activation Protein; Red) captured on a
   CyteCatch slide from a metastatic breast cancer patient.
   
    
   
   Photo courtesy of Dorraya El-Ashry, PhD.
   
    
   
   URINE-BASED CYTOLOGY
   
    
   
   STANDARD CYTOLOGY FOR THE DETECTION OF ATYPICAL CELLS IN VOIDED URINE FROM
   BLADDER CANCER PATIENTS COMMONLY CONTAINS NON-TUMOR BLOOD CELLS AND OTHER
   DEBRIS THAT LIMIT INTERPRETATION BY A PATHOLOGIST. SAMPLE PROCESSING BY THE
   FACTCHECKER ELIMINATES THESE MATERIALS, ALLOWING FOR DIAGNOSES TO BE MORE
   EASILY MADE, SPECIFICALLY IN CASES WHERE BACKGROUND CONTAMINANTS SEVERELY
   LIMITS SAMPLE EVALUATION.
   
    
   
   Pictured: PAP stain of Atypical urothelial tumor cells from a bladder cancer
   patient enriched onto a CyteCatch slide, where cell morphology is clearly
   presented and confounding background is significantly reduced.

 * THE TEAM
   
   LEADERSHIP AT CIRCULOGIX
   
   RAM DATAR, MPHIL, PHD
   
   CHIEF EXECUTIVE OFFICER
   
   
   
   SIDDARTH RAWAL, MD
   
   CHIEF OPERATING OFFICER
   
   
   
   ANTHONY WILLIAMS, PHD
   
   CHIEF SCIENTIFIC OFFICER
   
   
   
   SUNG-JIN KIM, PHD
   
   CHIEF TECHNICAL OFFICER
   
   
   
   RICHARD COTE, MD, FRCPATH
   
   CHIEF MEDICAL OFFICER
   
   

 * CIRCULOGIX IN THE NEWS
   
   
   
   9.25.2017
   
   CIRCULOGIX CSO DR. ANTHONY WILLIAMS HONORED AS A 2017 "MINORITY SCHOLAR IN
   CANCER RESEARCH" BY AACR FOR WORK ON DISPARATE PROSTATE CANCER AGGRESSIVENESS
   IN AFRICAN-AMERICAN MEN.
   
   http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=106&DetailItemID=638#.WiwbcbQ-f_Q
   
   1.28.2015
   
   DR. RICHARD COTE - CIRCULOGIX, INC CMO AND DIRECTOR OF THE DR. JOHN T.
   MACDONALD FOUNDATION BIOMEDICAL NANOTECHNOLOGY INSTITUTE AT UNIVERSITY OF
   MIAMI (BIONIUM), AND DR. RAM DATAR - CEO AT CIRCULOGIX, INC AND CO-DIRECTOR
   OF BIONIUM, UNVEIL SOUTH FLORIDA'S MOST EXPANSIVE AND ADVANCED CLEAN ROOM
   FACILITY FOR NANO FABRICATION AND BIOMEDICAL RESEARCH.
   
   http://www.miamiherald.com/living/health-fitness/article8539388.html
   
   6.13.2013
   
   CIRCULOGIX CSO ANTHONY WILLIAMS SECURES THE PRESTIGIOUS UNCF-MERCK SCIENCE
   INITIATIVE "GRADUATE FELLOWSHIP AWARD" TO FUND GROUNDBREAKING RESEARCH IN
   VIABLE CTC CULTURE CHARACTERIZATION.
   
   http://www.businesswire.com/news/home/20130613006129/en/37-African-American-Students-Awarded-Prestigious-UNCF%E2%80%A2Merck-Science
   
   2.07.2012
   
   CIRCULOGIX CEO DR. RAM DATAR RECEIVES THE COVETED "JEWEL OF INDIA AWARD" FOR
   OUTSTANDING ACCOMPLISHMENTS AND LEADERSHIP IN EXPERIMENTAL AND MOLECULAR
   PATHOLOGY.
   
   http://med.miami.edu/news/dr.-ram-h.-datar-named-to-prestigious-hind-rattan-award
   
   2.07.2012
   
   CIRCULOGIX CMO DR. RICHARD COTE NAMED FIRST JOSEPH R COULTER, JR ENDOWED
   CHAIR OF PATHOLOGY AT THE UNIVERSITY OF MIAMI.
   
   http://med.miami.edu/news/richard-cote-m.d.-named-first-joseph-r.-coulter-jr.-endowed-chair-in-pathol


 * CONNECT WITH US
   
   FOLLOW US USING THE LINKS BELOW FOR ALL OF THE LATEST UPDATES ON CIRCULOGIX
   PRODUCTS, NEW DEVELOPMENTS AND MOST RECENT AND EXCITING RESEARCH FINDINGS
   
   Email
   
   info@circulogixinc.com
   
   LinkedIn
   
   Under Construction
   
   Twitter
   
   Under Construction
   
   Facebook
   
   Under Construction
   
   




© 2017








Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume
you accept the use of cookies.
Accept
Learn More